Ligand Pharmaceuticals stock reports stronger royalty growth after Q2 results

Published on 10/04/2026 at 20:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ligand Pharmaceuticals stock was last at USD 302.96 on October 2, 2026. Q2 revenue reached USD 63.69 million, up 33.8 percent year over year.

LGND, US53220K5048, Illustration mit AI erstellt.

Ligand Pharmaceuticals stock (ISIN US53220K5048) was last at USD 302.96 on Nasdaq on October 2, 2026, with a market capitalization of USD 6.1 billion. The company’s second-quarter results showed revenue of USD 63.69 million, up 33.8 percent from the year-earlier quarter, according to StockTitan.

Royalty revenue drives Q2 growth

Royalty revenue reached USD 48.0 million in Q2 2026, compared with USD 36.4 million in Q2 2025, a 32 percent increase. Adjusted diluted earnings per share rose 48 percent year over year to USD 2.37, while GAAP diluted earnings per share was USD 2.22, according to StockTitan.

Ligand reaffirmed 2026 revenue guidance of USD 270 million to USD 310 million and raised its adjusted EPS guidance to USD 9.00 to USD 9.50. The Q2 figures matter because the royalty stream, rather than a single product launch, is becoming the central measure of the company’s operating performance.

Analysts price in further upside

MarketBeat reported on September 28, 2026, that all 10 covering analysts rated Ligand Pharmaceuticals Buy, with an average 12-month price target of USD 337.89. That target lies 11.5 percent above the October 2 Nasdaq price of USD 302.96, according to MarketBeat. The same report cited recent targets of USD 345 from Barclays, USD 358 from HC Wainwright and USD 388 from Bank of America.

Barclays initiated coverage on September 25, 2026, with an Overweight rating and a USD 345 price target, as MarketBeat reported. The range between the average target and the latest Nasdaq price leaves execution of the royalty portfolio as the key test for the valuation.

New financing expands the pipeline

On September 24, 2026, Ligand announced a financing agreement with AvenCell Therapeutics for up to USD 47 million. The commitment includes up to USD 41 million for royalty rights and up to USD 6 million in Series C financing, with future funding tied to clinical milestones, according to Ligand Pharmaceuticals. AvenCell’s lead programs target relapsed or refractory acute myeloid leukemia and B-cell malignancies.

Ligand Pharmaceuticals stock stays near its yearly high

Ligand Pharmaceuticals stock was last at USD 302.96 on Nasdaq on October 2, 2026, with a 52-week range of USD 175.89 to USD 326.63 and volume of 179,228 shares. The latest price is 7.2 percent below the 52-week high, placing the market’s attention on whether royalty growth and the enlarged asset portfolio can support the premium valuation.